Anmeldung erfolgt in Kürze...
Details werden geladen...
ADA in 30 Seconds: Competition for obesity drugs, clinical blind spots, and more | STAT
You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.
Ähnliche Seiten
ADA in 30 Seconds: Triple-G safety data, a monthly obesity drug, and more | STAT
https://www.statnews.com/2026/06/06/triple-g-safety-data-monthly-obesity-drug-ada-in-30/ADA in 30 Seconds: Newer GLP-1s, pushback on research cuts, and a protest | STAT
https://www.statnews.com/2026/06/05/newer-glp-1s-pushback-on-research-cuts-and-a-protest-ada-in-30/Lilly shares safety, tolerability data on its next-gen obesity drug | STAT
https://www.statnews.com/2026/06/06/illy-retatrutide-triple-g-weight-loss-obesity-safety-data-ada/At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
https://www.statnews.com/2026/05/29/asco-news-day-1-multiple-myeloma-bristol-lung-cancer-pfizer/
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 a...
https://www.manilatimes.net/2026/06/08/tmt-newswire/pr-newswire/ascletis-reinforces-its-differentiated-obesity-portfolio-at-american-diabetes-association-ada-2026-scientific-sessions-showcasing-asc30-clinical-data-and-exciting-preclinical-findings-from-asc37-and-asc39/2360317